In a regulatory filing, the company said the EIR was issued following an inspection conducted by the US FDA at the Nagpur injectable facility from September 8 to September 16, 2025. Shares of Lupin Ltd ended at ₹2,085.90, down by ₹6.70, or 0.32%, on the BSE.
